Baxter International Inc. filings document formal disclosures for a NYSE-listed medtech issuer with common stock and listed global notes. Recent 8-K reports furnish earnings releases, financial-condition updates, dividend declarations, Regulation FD stockholder-engagement materials, executive leadership changes, severance and change-in-control arrangements, and exhibits tied to material corporate actions.
The company’s proxy materials cover board governance, stockholder voting matters, executive compensation and pay-versus-performance disclosures. Debt-related filings describe senior note issuances, supplemental indentures, underwriting arrangements and tender offers, while recurring reports identify registered securities, capital-structure actions and governance controls relevant to Baxter’s medical-device and healthcare-products business.
Baxter International Inc. increased the Maximum Tender Cap for its previously announced cash tender offer for its 1.915% senior unsecured notes due 2027 to $600 million, up from the prior cap of $300 million. This means Baxter is now willing to buy back a larger amount of these 2027 notes for cash than originally planned.
The change, announced on November 19, 2025, affects only the 1.915% notes due 2027 and is governed by the company’s offer to purchase dated the same day. The update is described as part of a tender offer process rather than an offer to sell or solicit new securities.
Baxter International Inc. announced that it has started cash tender offers for certain outstanding debt securities. The company is offering to purchase any and all of its 2.600% senior unsecured notes due 2026 and a portion of its 1.915% senior unsecured notes due 2027, for an aggregate purchase price of up to $300 million, an amount that may be increased, decreased or eliminated under the terms of its offer to purchase dated November 19, 2025. The tender offers are being made only under that offer to purchase and are subject to applicable securities and other laws in relevant jurisdictions.
Dodge & Cox filed Amendment No. 4 to a Schedule 13G reporting a significant passive stake in Baxter International (BAX). The firm beneficially owns 57,396,370 shares, representing 11.2% of Baxter’s common stock. It has sole voting power over 54,118,570 shares and sole dispositive power over 57,396,370 shares.
Dodge & Cox is identified as an investment adviser and certifies the shares were acquired and are held in the ordinary course of business and not to change or influence control. Its clients have rights to receive dividends and sale proceeds. The Dodge & Cox Stock Fund holds 38,623,700 shares, or 7.5% of the class. The reported event date is 09/30/2025.
Baxter International Inc. announced a leadership change: Alok Sonig has resigned as Executive Vice President and Group President, Pharmaceuticals. His resignation is effective December 1, 2025, and he is departing to join a company in the healthcare industry.
The update was disclosed in a current report and pertains only to this executive transition. Baxter’s common stock trades on the NYSE under BAX, and its 1.3% Global Notes due 2029 trade as BAX 29 on the NYSE.
Baxter International (BAX) reported Q3 2025 results with net sales of $2,835 million, operating income of $172 million, and a loss from continuing operations of $51 million after $172 million of income tax expense. Net loss was $46 million. Gross margin was $950 million versus $1,033 million a year ago, while interest expense fell to $58 million from $87 million.
The company closed the sale of its Kidney Care business on January 31, 2025, receiving approximately $3.71 billion in pre-tax cash at closing and recognizing a year-to-date pre-tax gain of $115 million. Final working capital adjustments reduced the Q3 gain by $55 million. Year-to-date, Baxter repaid $3,505 million of debt, including retiring a $1.83 billion bridge facility, and cut long-term debt to $8,747 million from $10,374 million, with only $4 million of short-term debt outstanding. The amended $2.20 billion multicurrency revolver had no borrowings at quarter-end.
Baxter recorded Hurricane Helene-related charges of $8 million in Q3 and $123 million year-to-date. The company initiated Class I recalls for the Novum IQ Large Volume Pump and temporarily stopped distribution in the U.S. and Canada, recording a remediation reserve that was not material.
Baxter International Inc. filed an 8-K announcing it furnished an earnings press release for the period ended September 30, 2025. The press release is attached as Exhibit 99.1. The company states the information in Item 2.02, including Exhibit 99.1, is being furnished and shall not be deemed filed under the Exchange Act. Exhibits also include the Cover Page Interactive Data File as Exhibit 104.
Baxter International (BAX) announced a leadership change. Heather Knight will resign as Executive Vice President, Chief Operating Officer, and interim group president of Medical Products and Therapies (MPT) effective October 29, 2025, to join a company in the healthcare industry.
On the transition date, President and CEO Andrew Hider will also serve as interim group president of MPT, and Baxter will eliminate the COO role. This consolidates operational oversight under the CEO while the company manages the MPT leadership transition.
BlackRock Portfolio Management LLC filed a Schedule 13G/A reporting beneficial ownership of 39,204,985 shares (7.6%) of Baxter International (BAX) common stock as of 09/30/2025.
The filer reports 38,736,192 shares with sole voting power and 39,204,985 shares with sole dispositive power. The certification states the securities were acquired and are held in the ordinary course and not to change or influence control.
Alok Sonig, EVP & Group President, Pharma at Baxter International (BAX), reported a transaction on 09/02/2025. He relinquished 3,191 shares of Baxter common stock at a price of $24.17 per share to cover tax withholding tied to the delivery of vested restricted stock units granted on 09/01/2022. After the transaction, the reporting person beneficially owns 128,219 shares, which the filing notes includes automatic dividend reinvestment. The sale was reported on a Form 4 signed by an attorney-in-fact on 09/04/2025.
Andrew P. Hider, President and CEO and Director of Baxter International Inc. (BAX), reported issuance of equity awards on 09/02/2025. He received 236,237 restricted stock units (RSUs) as a make-whole award for unvested prior employer equity and 131,813 RSUs as a pro rata 2025 annual grant, bringing his total reported common stock beneficial ownership to 368,050 shares after the transactions. He also received stock options covering 465,651 shares with a $24.17 exercise price, exercisable in three equal annual installments beginning 09/02/2026 and expiring 09/02/2035. The RSUs vest in three equal annual installments starting 09/02/2026, with accelerated vesting on certain termination events. The Form 4 was signed by an attorney-in-fact on 09/04/2025.